A safe and effective vaccine for preventing respiratory syncytial virus (RSV), a common and sometimes serious respiratory infection, had eluded biopharma for decades. But in 2023, the world saw the first – and second – vaccine hit the market.
Poolbeg Pharma plc has reported promising outputs from its lab-based analysis of respiratory syncytial virus (RSV) drug targets and treatments identified as part of the company’s artificial intelligence (AI)-led program.
Limmatech Biologics AG and Abvacc Inc. have entered into a license agreement that grants Limmatech the exclusive rights to further develop Abvacc’s multivalent toxoid vaccine candidate, LBT-SA7 (formerly IBT-V02), designed to prevent infections caused by Staphylococcus aureus.
Researchers have used explainable artificial intelligence (explainable AI) to find structurally new antibiotics with minimal toxicity. They reported their findings online in Nature on Dec. 20, 2023. In animal testing, compounds identified via the method showed that they had activity against drug-resistant gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), one of the most serious bacterial public health threats.
Sirnaomics Ltd.'s subsidiary Rnaimmune Inc. has received IND clearance from the FDA to begin trials of RV-1770, an mRNA vaccine targeting the human respiratory syncytial virus (RSV) to prevent RSV infection in adults. Rnaimmune will conduct a phase I study of RV-1770 administered intramuscularly in healthy adults.
Nrx Pharmaceuticals Inc. has announced FDA clearance of its IND application for the use of NRX-101 (lurasidone hydrochloride/D-cycloserine) for the treatment of complicated urinary tract infections (cUTI).
Recce Pharmaceuticals Ltd. has announced preclinical results from an in vivo study evaluating the antibacterial efficacy of its lead synthetic anti-infective candidate, R-327 (RECCE-327), against Neisseria gonorrhoeae in a mouse vaginal infection model.
The Novo Nordisk Foundation is committing up to DKK1.8 billion (US$260 million) to establish a research and vaccine development initiative that aims to create new or improved vaccines for respiratory diseases, including tuberculosis (TB) and influenza.
Leishmaniasis is a vector-borne infectious disease caused by several protozoan Leishmania species with diverse clinical manifestations and limited treatment options to date. Researchers at Drugs for Neglected Diseases initiative have reported on the discovery and preclinical characterization of DNDI-6174, a novel inhibitor of the Leishmania cytochrome bc1 complex.
Gilead Sciences Inc. has synthesized indoline compounds acting as viral replication inhibitors reported to be useful for the treatment of herpes simplex virus infection and herpes simplex virus encephalitis.
RSS
